Literature DB >> 6289455

Nuclear renal imaging in acute pyelonephritis.

H Handmaker.   

Abstract

Patients with acute pyelonephritis may present with a spectrum of clinical signs and symptoms. There are few noninvasive diagnostic studies, however, to confirm or exclude this diagnosis. A small number of patients, generally those with severe disease, will demonstrate radiographic changes on excretory urography, but the lack of sensitivity of the IVP in early, acute pyelonephritis is well documented. Several radionuclide techniques have been proposed to assist in the earlier detection of this clinical problem including imaging with Mercury-197 chlormerodrin, Gallium-67 citrate, Technetium-99m glucoheptonate. Technetium-99m DMSA, and, more recently, Indium-111 labeled white blood cells. The success of the renal cortical imaging agents as well as those which localize in infection are described in this report. There appears to be a complimentary role or the cortical imaging agents and the radiopharmaceuticals which localize in bacterial infection. Cortical agents offer the advantage of specific assessment of functioning renal tissue and a convenient, rapid method for following the response to treatment in a noninvasive manner. A pattern is described which may be diagnostic; correlation with Gallium-67 citrate of Indium-111 WBCs may increase the probability of infection as the cause for the cortical abnormality. The measurement of differential renal function using cortical agents provides additional information to assist the clinician in predicting the late effects of infection. Improved sensitivity and specificity, and a reproducible method for following the response to therapy in patients with acute pyelonephritis are the advantages of the techniques described.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289455     DOI: 10.1016/s0001-2998(82)80039-1

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  9 in total

1.  Extent of urinary tract involvement and imaging in childhood urinary tract infections.

Authors:  Z E Bircan; N Buyan; E Hasanoğlu; E Oztürk; H Bayhan; S Işik
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

2.  Intra- and interobserver variability in interpretation of DMSA scans using a set of standardized criteria.

Authors:  K Patel; M Charron; A Hoberman; M L Brown; K D Rogers
Journal:  Pediatr Radiol       Date:  1993

3.  99mTechnetium dimercaptosuccinic acid scintigraphy in the diagnosis of acute pyelonephritis in rats.

Authors:  I Wikstad; L Hannerz; A Karlsson; A C Eklöf; S Olling; A Aperia
Journal:  Pediatr Nephrol       Date:  1990-07       Impact factor: 3.714

4.  Radiologic evaluation of urinary tract infection.

Authors:  Z E Bircan; N Buyan; E Hasanoğlu; E Oztürk; H Bayhan; S Işik
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

5.  Comparison of reliability of tests to distinguish upper from lower urinary tract infection.

Authors:  G H Schardijn; L W Statius van Eps; W Pauw; C Hoefnagel; W J Nooyen
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-04

6.  The importance of 99mTc DMSA scanning in the localization of childhood urinary tract infections.

Authors:  N Buyan; Z E Bircan; E Hasanoğlu; E Oztürk; H Bayhan; S Rota
Journal:  Int Urol Nephrol       Date:  1993       Impact factor: 2.370

7.  The localization of urinary tract infection with 99mTc glucoheptonate scintigraphy.

Authors:  E S Traisman; J J Conway; H S Traisman; R Yogev; C Firlit; A Shkolnik; S Weiss
Journal:  Pediatr Radiol       Date:  1986

8.  Febrile renal transplant recipient with discordant findings of (99m)Tc-Leukoscan (Sulesomab) and (67)Ga-citrate scan in pyelonephritis.

Authors:  Sunita Tarsarya Sonavane; Atul Marwah; Rajnath Jaiswar
Journal:  Indian J Nucl Med       Date:  2011-10

9.  Tc-99m dimercaptosuccinic acid(DMSA) renal scintigraphy in patients with acute pyelonephritis.

Authors:  K W Lee; K T Bin; M S Jeong; M H Shong; Y T Shin; H K Ro
Journal:  Korean J Intern Med       Date:  1995-01       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.